You just read:

Braeburn Pharmaceuticals and Camurus announce positive top line results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder

News provided by

Braeburn Pharmaceuticals , Camurus

May 11, 2016, 02:00 ET